Press "esc" to clear
Go to Advanced Search
Showing results 1120 of 3202
  • Embargo expired:
    22-Oct-2018 12:00 PM EDT

Article ID: 702534

Combined therapy including pelvic lymph node radiation provides significant benefit for prostate cancer patients

American Society for Radiation Oncology (ASTRO)

The first report of a large international clinical trial shows that, for men who show signs of prostate cancer after surgical removal of their prostates, extending radiation therapy to the pelvic lymph nodes combined with adding short-term hormone therapy to standard treatment can extend the amount of time before their cancer spreads. Findings will be presented in a news briefing today at noon ET from the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Released:
22-Oct-2018 12:00 AM EDT
  • Embargo expired:
    22-Oct-2018 12:00 PM EDT

Article ID: 702535

Radiation Therapy Outcomes Better for African-American Prostate Cancer Patients Than Caucasian Patients

American Society for Radiation Oncology (ASTRO)

While popular beliefs and population data suggest that African-American men are at higher risk of dying from prostate cancer than Caucasian men, a new analysis of genetic data from a large prospective registry and clinical data from several randomized trials indicates that African-American patients may have comparatively higher cure rates when treated with radiation therapy. Findings will be presented in a news briefing today at noon ET from the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Released:
21-Oct-2018 11:05 PM EDT
  • Embargo expired:
    22-Oct-2018 12:00 PM EDT

Article ID: 702536

Men with low- and intermediate-risk prostate cancer can safely benefit from fewer, higher-dose radiation treatments

American Society for Radiation Oncology (ASTRO)

Stereotactic body radiation therapy (SBRT) is a safe and effective treatment for men with low- and intermediate-risk prostate cancer, according to a long-term, multi-institutional study. The study clears the way for patients who may wish to shorten their course of treatment without fear of increasing their risk for severe, adverse side effects. Findings will be presented in a news briefing today at noon ET from the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Released:
21-Oct-2018 11:05 PM EDT
  • Embargo expired:
    22-Oct-2018 12:00 PM EDT

Article ID: 702537

High-dose, high-precision radiation therapy safe and effective for kidney cancer patients with only one kidney

American Society for Radiation Oncology (ASTRO)

Treatment of renal cell carcinoma with stereotactic radiation therapy is as safe and effective for patients with one kidney as it is for those who have two, according to an analysis of the largest-ever, international dataset of solitary kidney patients to receive this emerging treatment. Findings will be presented in a news briefing today at noon ET from the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Released:
21-Oct-2018 11:05 PM EDT

Article ID: 702545

Media Call-in Opportunity Today

American Neurological Association (ANA)

For the first time, the American Neurological Association’s 143rd Annual Meeting will feature a media roundtable TODAY, October 22, 2018 from 11:50-1:00 p.m. at which presenters of the six principal symposia will present highlights, discuss the relevance of the work, and answer questions.

Released:
22-Oct-2018 9:15 AM EDT
Embargo will expire:
27-Oct-2018 7:30 PM EDT
Released to reporters:
22-Oct-2018 8:00 AM EDT

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 27-Oct-2018 7:30 PM EDT

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Embargo will expire:
25-Oct-2018 7:30 PM EDT
Released to reporters:
22-Oct-2018 8:00 AM EDT

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 25-Oct-2018 7:30 PM EDT

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Embargo will expire:
26-Oct-2018 7:30 PM EDT
Released to reporters:
22-Oct-2018 8:00 AM EDT

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 26-Oct-2018 7:30 PM EDT

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Embargo will expire:
25-Oct-2018 7:30 PM EDT
Released to reporters:
22-Oct-2018 8:00 AM EDT

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 25-Oct-2018 7:30 PM EDT

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Embargo will expire:
25-Oct-2018 12:45 PM EDT
Released to reporters:
22-Oct-2018 8:00 AM EDT

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 25-Oct-2018 12:45 PM EDT

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.


Showing results 1120 of 3202

Chat now!